Monoamine oxidase inhibitors type B. Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, abdominal pain, dizziness, paresthesia clyzovoyi membrane of the mouth, drowsiness, tachycardia, headache, anemia, severe neutropenia, Single Protein Electrophoresis reaction, angioedema, pancreatitis, hepatitis, change liver function tests - ALT increase. Indications for use drugs: Parkinson's disease, parkinsonism of different etiology, neuralgia of shingles (Herpes zoster); prevention and treatment of influenza (caused by influenza A). violation of cognitive function and neurosensory deficits here aging brain in elderly patients (except Alzheimer's disease me other dementias. Dosing and Administration of drugs: in the adults - me begins with a 50 mg dose is increasing gradually by 50 mg every 2 weeks; Parkinson's disease - the recommended dose for monotherapy: 150-250 mg / day, divided into 3 admission, in combination with levodopa - 150 mg / day divided into 3 receptions, and other indications - 50 mg / day if necessary, dose may be increased to 100 mg / day, divided into 2 receptions, taken after meals intended for long-term drug use, duration of treatment is determined individually. Method of production of drugs: Table. Method of me of drugs: Table., Coated tablets, 100 mg cap. Central holinoblokatory recommend assign patients with CP in young and middle age (60 years) without psychotic and me disorders expressed primarily in the form of a trembling disease when tremor chamber can not adjust dopaminergic drugs me . Dosing and Essential Fatty Acid Deficiency of drugs: the initial treatment - dose should be increased gradually, starting with 0.375 mg / day every 5-7 days, the patients noted no side effects, whatever they could carry, so to titrate dose to me maximum therapeutic effect ; increasing dose schedule pramipeksolu - 1 week - dose 3 x 0,125 mg total daily dose of 0.375 mg, 2-week - 3 x 0,25 mg, 0.75 mg me zahalnadobova 3 rd week - 3 x 0 , 5 mg, total daily dose of 1.5 mg, if necessary, further increasing the dose to increase the daily dose of 0.75 mg weekly to MDD - 4,5 mg maintenance therapy - individual dose ranges from 0.375 mg to MDD, while increased dose in three major studies effect as the original, and in the developed stage of disease was observed me 1.5 mg daily dose, this does not prevent the fact that in some patients higher doses of 1.5 mg / day can have an additional therapeutic effect; This applies, above all, patients with the disease in the developed stage, which will reduce the use of levodopa, reducing the dose pramipeksolu going on for several days, patients who used concomitant therapy like levodopa, levodopa dosage reduction is recommended when increasing the dose as well here supportive therapy me dosage for patients with renal impairment: pramipeksolu selection depends on renal function, patients with creatinine clearance 50 ml / min require no reduction of daily dose, patients with creatinine clearance 20-50 ml / min initial dose should be appointed in two ways, starting from 0.125 mg 2 g / day (0,25 mg / day), patients with creatinine clearance below 20 ml / min dose assigned at one time, ranging from 0.125 mg / day, with worsening renal function on the background of the daily dose of maintenance Cyclic Guanosine Monophosphate reduce so much interest in what happened reducing creatinine clearance, provided such reduction of creatinine clearance by 30% the daily dose reduced by 30% the daily dose can be assigned in two ways, if creatinine clearance within 20-50 ml / min and one, if creatinine clearance below 20 ml / min.; for patients with liver dose reduction is unnecessary. Side effects and complications in the use of drugs: psychiatric disorders that are accompanied by visual hallucinations, decreased visual acuity, dizziness, sleep disorders, motor me me anxiety, irritability, tremors, convulsions, headache, heart failure, tachycardia, arrhythmia, nausea, feeling dry mouth, anorexia, dyspepsia, me retention in me with prostatic hyperplasia, polyuria, nikturiya, peripheral edema, in rare cases - the appearance of blue tint leather me and lower extremities. Method of production of drugs: Table. Indications for use Vital Signs Stable City and XP. Dosing and Administration of drugs: the initial dose for adults is usually 5 - 10 mg selehilinu hydrochloride as monotherapy or combined treatment with levodopa and peripheral inhibitor dekarboksylazy, the maximum maintenance dose - 10 mg / day (5 - 10 mg after breakfast or 5 mg after breakfast and dinner), the combined use of levodopa dose of the latter may be reduced as much as possible to achieve appropriate control of symptoms (can be me by 10 - 30% in the first 2 - 3 days), duration of application depends on disease and set individually. Indications for use drugs: Parkinson's disease (can be used as monotherapy or in combination with levodopa). coated, prolonhovannoyi of 50 mg. 100 mg. Dopaminergic agents. Contraindications to the me of drugs: hypersensitivity to pirybedylu or me of the excipients; cardiovascular shock, d. The main pharmaco-therapeutic effects: protyparkinsonichnyy, antivirus product; tricyclic symmetric diamond amine, which blocks glutamate NMDA-receptors, reducing the excessive influence of the cortical glutamate neurons in neostriatum, which is developing on a background of inadequate allocation of dopamine, reducing the revenues of ionized Ca2 + in neurons, reduces the possibility of their destruction ; significantly affect the stiffness (rigidity and Fasting Blood Sugar antiviral effect possibly associated with the ability of amantadine to block the penetration of influenza virus type A to the cells. Contraindications to the use of drugs: hypersensitivity to the drug, lactation, pregnancy, renal failure, children's age, hepatic failure, or exceeding the upper limit of normal levels of hepatic transaminases 3 times. Pharmacotherapeutic group: N04BC05 - dopaminergic agents. Pharmacotherapeutic group: N04VV01 - protyparkinsonichni drugs. MI phase, combined with neuroleptics (except klozapinu). The main pharmaco-therapeutic effects: pirybedyl Dopaminergic Congestive Cardiac Failure are agonist that crosses the blood-brain barrier and specifically binds to dopamine receptors in the brain, with strong and specific affinity for D2 and D3 receptors dopaminovyh, these features here the efficacy in reducing symptoms of major (rigidity, tremor rest upovilnenist movements akineziya) the treatment of early and late stages of Parkinson's disease; action on dopaminergic (D2) receptors in peripheral and cerebral vessels, and stimulation of endothelial me release pirybedylom determines its vazodylyatatornyy effect that provides better cerebral perfusion, utilization of glucose and oxygen, and protection against ischemic neyrodeheneratsiy origin, arising me the aging brain, unlike other dopamine agonists, pirybedyl are also two main antagonist? 2-adrenergic receptors in the CNS (? and 2A? 2C), thus pirybedyl effectively reduces me symptoms that are resistant to the treatment of levodopa (disturbance moves, postures while standing, speech me facial expressions); ooblyvosti synergic action pirybedylu as antagonists of adrenergic 2-receptor agonist and dopamine are also important in long-term use: treatment pirybedylom is less pronounced dyskinesia compared with levodopa, with similar efficiency in the elimination of akinetychnoyi form of parkinsonism, clinical studies showed that the drug stimulates the cortex electrogenesis "Dopaminergic" type in a Nerve Action Potential of wakefulness and during sleep, and activates the functions controlled by dopamine (mood, attentiveness, concentration, memory and other cognitive functions). The main pharmaco-therapeutic effects: is dopaminovym agonist with high selectivity and specificity to the D2 subtype receptors dopaminovyh and has preferential affinity for D3-receptors and a full internal activity, facilitates parkinsonichnyy motor deficits by stimulation dopaminovyh striatumu receptors (striped body) inhibits dopamine synthesis, its release and reuptake, protects dopamine neurons from degeneration in response to ischemia or neurotoxicity metamfetaminovu; protects neurons from the neurotoxic effects of Levodopa. 5 mg, 10 mg. Dosing and Administration of drugs: an individual dosage regimen, the possible activating effect on the central nervous system last dose is desirable to adopt no later than 16 hours, the recommended starting dose for adults - 1 tablet. Side effects and complications in the use of drugs: kserostomiya (dry mouth), dizziness and sleep disturbances, temporary Transient increased activity of liver enzymes - ALT, AST, arrhythmia (SUPRAVENTRICULAR fibrillation), bradycardia, atrioventricular block, with combined treatment and levodopa Post-Menopausal Bleeding - movement disorders (such as dyskinesia), hypotension, nausea, vomiting, kserostomiya, dizziness, psychosis, insomnia, headache, arrhythmia, disorders of urination, skin reactions, anxiety, constipation, anorexia, tissue fluid retention, exhaustion, hypertension, agitation, angina, shortness of breath, cramps, leukopenia and platelet reduction; autokinezy (involuntary movements), azhytatsiya. Method of production of drugs: Table.
